One major focus of Dr. Li and colleagues in Dr. Kimberly’s group is studying immunoglobulin receptors (Fc receptors) and their functions. Understanding the role of Fc receptors is critical to the development of effective antibody-based therapeutics. Until recently, FcγRIIb was the only known classical IgG receptor on B cell. When engaged, FcγRIIb counteracts activation induced by B cell receptor. Dr. Li’s recent publication has reported that a second IgG receptor, FcγRIIc, exists on B cells in an allele-dependent manner. When this receptor is expressed, it counterbalances the negative feedback mediated by FcγRIIb, thus, revising the classical paradigm of immune regulation. This paradigm-shifting discovery was independently reported by SciBx, a weekly Nature publication focusing on scientific discoveries expected to have significant translational impact and commercial value.